Vycor Medical, Inc. (OTCQB: VYCO), a company specializing in innovative surgical and therapeutic solutions, announced its financial results for the three and six months ended June 30, 2026. The report reveals a mixed performance, with a decline in revenue for its Vycor Medical division but notable advancements in clinical evidence supporting its flagship product.
For the three months ended June 30, 2026, total revenue decreased 16% to $418,264, compared to $496,353 in the same period last year. The Vycor Medical division, which markets the ViewSite Brain Access System (VBAS), generated $401,224, a 17% drop from $481,788, primarily attributed to a decrease in international sales. The NovaVision division, still in development, contributed $17,040, a 17% increase from $14,565. Gross profit for the quarter was $344,445, yielding a margin of 82%, slightly down from 83% in 2025.
For the six-month period, revenue fell 6% to $876,804 from $932,731. Vycor Medical division revenues decreased 7% to $841,665, with declines split between U.S. and international markets. NovaVision revenues grew 8% to $35,139. Gross profit for the six months was $719,598, with an 82% margin.
Operating profit for the quarter was $6,851, a significant drop from $51,146 in the prior year, while for the six months, operating profit increased to $52,659 from $38,340. On a non-GAAP basis, which excludes non-cash items like depreciation and stock-based compensation, operating profit for the quarter was $22,952 compared to $85,712, and for the six months was $82,740 versus $106,100.
Despite the revenue decline, Vycor Medical highlighted the publication of three new peer-reviewed studies on the VBAS system during 2026, bringing the total to 53 peer-reviewed clinical papers and 14 other clinical papers. One study focused on a complex pediatric tumor case, emphasizing the effectiveness of combining neuro-navigation systems with VBAS. Another retrospective study of 23 patients undergoing tumor resection found that those using VBAS had significantly fewer new neurological deficits compared to traditional blade retractors, implying safer tumor resection. The most recent study reported on minimally invasive suboccipital tubular resection for posterior fossa metastases, concluding that this approach enables effective decompression with low cerebrospinal fluid diversion rates.
These studies reinforce the clinical benefits of VBAS, which is FDA-cleared and used in over 350 hospitals in the U.S. and internationally. The system is protected by 49 issued and 8 pending patents.
The NovaVision division, which offers vision rehabilitation therapies for stroke and brain injury patients, continued to show growth. Its Visual Restoration Therapy (VRT) is the only FDA-cleared therapy for vision rehabilitation following neurological damage. The complementary NeuroEyeCoach program has demonstrated improvement in over 80% of patients.
The company’s GAAP net loss for the quarter was $22,288, or $0.00 per share, compared to net income of $23,887 in the prior year. For the six months, net loss available to common stockholders was $164,365, largely due to preferred stock dividends.
Vycor Medical’s management remains focused on advancing its product portfolio and expanding clinical evidence to drive long-term growth, despite short-term revenue fluctuations.
